In a time when tradition seamlessly intertwines with modern advancements, the traditional Chinese medicine (TCM) sector is embarking on a remarkable journey of growth. Sichuan Neautus Traditional Chinese Medicine Co., Ltd. (“Neautus”), a frontrunner in the industry, is committed to pursuing a path of high-quality development.

Neautus’ progression towards public listing showcases strategic decision-making at its finest. The transition from the A-share market to the Hong Kong stock market represents a deliberate and forward-thinking upgrade, a move grounded in a thorough analysis of market dynamics, corporate governance, and a global expansion strategy.

In 2011, during its initial A-share application, the Company encountered an inquiry report. After thorough verification from the sponsor and other intermediaries, it was confirmed that there were no issues. Following this verification, the Company entered an eight-month waiting period, during which there were no further inquiries from regulators. For Neautus, this time served as a “strategic reassessment phase.” It was an opportunity for the Company to re-evaluate its equity structure, development strategy, and overall alignment with the capital market.

At that time, the controlling shareholder’s investment was relatively modest, which could have limited the ability to implement significant strategic initiatives. Consequently, the Company chose to pause its IPO process to focus on enhancing internal governance and optimizing its equity structure. The broader market conditions also played a role, as major indices experienced sharp declines between 2011 and 2012, further encouraging the Company to make these strategic adjustments.

Then the company strategically shifted its focus from relatively low gross profit margin traditional Chinese medicine decoction pieces for TCM patent medicine factories and non essential high-quality decoction pieces such as cordyceps to more stable gross profit margin, broader market, and essential medical institution formula decoction pieces. This pivot has resulted in more stable profit margins, access to broader markets, and a steady demand, which has since confirmed the effectiveness of this approach.

Following this, Neautus quickly initiated a series of capital operations to fortify the Company’s core control, thereby enhancing the influence of the controlling shareholder and fostering greater cohesion within the Group. These well-planned strategic actions have established a stronger foundation for the Company’s future growth. This clearly indicates that the decision to withdraw the A-share listing application stemmed not from external skepticism but from a strategic choice aimed at refining internal governance.

After solidifying its internal structure, Neautus set its sights on the Hong Kong capital market, marking a pivotal step in its globalization strategy. The Hong Kong Stock Exchange offers not only a pathway for international expansion but also a regulatory framework that complements the improvements made within Neautus. Recently, many high-quality mainland enterprises have opted for "A-to-H" listings, and Neautus’ decision reflects this trend while positioning itself appropriately in a changing market landscape.

Neautus has established itself as a leader in the industry for over twenty years, showcasing its robust strengths in key areas such as industrial positioning, intelligent manufacturing, responsiveness to policies, and market engagement.

As noted in a Frost & Sullivan Report, Neautus secured second place in China’s TCM decoction-ready product market based on 2023 revenues, while leading among non-state-owned enterprises. Its recognition as a “Sichuan Province Advanced Smart Factory” underscores its exceptional capabilities in intelligent manufacturing, which serve as a significant competitive edge. With processes ranging from automated raw material feeding to comprehensive digital traceability, Neautus has effectively embraced the principles of Industry 4.0. This integration not only boosts efficiency but also upholds superior quality control, empowering the company with greater leverage in sourcing raw materials.

Moreover, Neautus’ approach aligns seamlessly with national policies. In contrast to the VBP scheme for generic medicines, the centralized procurement policy for TCM decoction-ready products prioritizes “high quality and competitive price", acknowledging the variations in quality among these products. This strategic alignment supports the sustainable growth of Neautus’ profit margins.

The Company has made significant strides in developing its online platform, “Jinfang Caotang (金方草堂).” This platform is specifically designed to serve over 86,000 traditional Chinese medicine clinics and outpatient departments across the country. Utilizing the innovative “Internet+” model, it effectively transcends traditional distribution channels and geographic barriers, resulting in a steady increase in the platform's engagement and impact.

The production of TCM decoction-ready products is a notably intricate process that requires stringent quality control, with varying levels of processing difficulty across different Chinese medicinal herbs. These factors naturally lend a degree of “flexibility” to the production lines of TCM decoction-ready products, leading to reasonable fluctuations in capacity that have become commonplace within the industry. Neautus serves a diverse customer base, including hospitals, medical institutions, pharmaceutical trade companies, pharmacies, and manufacturers. The company offers an extensive range of products, effectively catering to the varied needs of its clientele. This inherent flexibility in capacity is a key aspect of Neautus' competitive edge, as it optimizes production efficiency while maintaining high product quality, thus supporting the company’s ongoing business growth.

In the realm of TCM decoction-ready products, a tradition that spans thousands of years, Neautus stands out like Haidilao in the food sector and Laopu Gold in the precious metals market. With an unwavering commitment to quality and a constant drive for innovation, Neautus is not only setting new industry standards but also crafting a remarkable legacy for the future.

A New Dawn: Neautus' IPO Inspires a Transformation in Traditional Chinese Medicine